Home » Stocks » EMMA

Emmaus Life Sciences, Inc. (EMMA)

Stock Price: $1.33 USD 0.10 (8.13%)
Updated Jan 15, 2021 12:31 PM EST - Market closed
Market Cap 64.47M
Revenue (ttm) 7.46M
Net Income (ttm) -32.89M
Shares Out 46.02M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.33
Previous Close $1.23
Change ($) 0.10
Change (%) 8.13%
Day's Open 1.40
Day's Range 1.33 - 1.40
Day's Volume 2,333
52-Week Range 0.702 - 2.16

News

Hide News
  • All
  • Videos
  • Press Releases
GlobeNewsWire - 4 months ago

--Meeting Will be Open to the Public-- --Meeting Will be Open to the Public--

GlobeNewsWire - 5 months ago

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to t...

GlobeNewsWire - 5 months ago

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to t...

GlobeNewsWire - 5 months ago

--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in ...

GlobeNewsWire - 5 months ago

TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the ...

GlobeNewsWire - 5 months ago

TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EM...

GlobeNewsWire - 5 months ago

TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in...

GlobeNewsWire - 6 months ago

TORRANCE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease   treatment, is pleased to announce that it has engaged Partner ...

GlobeNewsWire - 6 months ago

TORRANCE, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously i...

GlobeNewsWire - 6 months ago

TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the...

GlobeNewsWire - 6 months ago

Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indi...

Zacks Investment Research - 11 months ago

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

About EMMA

Emmaus Life Sciences engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases.... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
George Carpenter
Employees
28
Stock Exchange
OTCMKTS
Ticker Symbol
EMMA
Full Company Profile

Financial Performance

In 2018, EMMA's revenue was $1.32 million, an increase of 923.74% compared to the previous year's $128,500. Losses were -$9.60 million, 34.9% more than in 2017.

Financial Statements